Compare IMVT & SAIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMVT | SAIC |
|---|---|---|
| Founded | 2018 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.4B |
| IPO Year | 2019 | 2013 |
| Metric | IMVT | SAIC |
|---|---|---|
| Price | $27.33 | $91.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 8 |
| Target Price | $30.78 | ★ $116.88 |
| AVG Volume (30 Days) | ★ 1.3M | 717.5K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 5.82 |
| Revenue | N/A | ★ $7,479,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.18 |
| P/E Ratio | ★ N/A | $15.74 |
| Revenue Growth | N/A | ★ 0.47 |
| 52 Week Low | $12.72 | $81.08 |
| 52 Week High | $29.25 | $124.11 |
| Indicator | IMVT | SAIC |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 46.62 |
| Support Level | $24.63 | $90.14 |
| Resistance Level | $27.71 | $104.11 |
| Average True Range (ATR) | 1.14 | 4.19 |
| MACD | 0.11 | 0.46 |
| Stochastic Oscillator | 55.65 | 58.63 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the Department of Defence (DoD) and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.